| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000026286 |
| Receipt No. | R000030139 |
| Scientific Title | Effect of a grain-derived processed product on visceral fat area |
| Date of disclosure of the study information | 2017/02/24 |
| Last modified on | 2019/07/30 (Ver. 4) |
| Basic information | ||
| Public title | Effect of a grain-derived processed product on visceral fat area | |
| Acronym | Effect of a grain-derived processed product on visceral fat area | |
| Scientific Title | Effect of a grain-derived processed product on visceral fat area | |
| Scientific Title:Acronym | Effect of a grain-derived processed product on visceral fat area | |
| Region |
|
|
| Condition | ||
| Condition | healthy human | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the effect of grain- derived processed product on visceral fat area |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | visceral fat area
12-wk after adoministration |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | control : product code ; A-001
12-wk repeated consumption Dose of l serving per day. visceral fat area measurement every 4-wk. |
|
| Interventions/Control_2 | active : product code ; B-001
12-wk repeated consumption Dose of l serving per day. visceral fat area measurement every 4-wk. |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1, 23<= BMI
2, 20<=Age< 60 of healthy men 3, provided written informed consent from subjects |
|||
| Key exclusion criteria | 1, liver, kidney and heart disease, or disorder of respiration endocrine, metabolism, nervous system consciousness, or diabetes, or other diseases
2, unpleasant feeling during blood drawing 3, donated 200 mL or more blood within l month before the trial 4, allergies against any constituents in the test diet 5, other clinical study or who intended to participate in one during the study period 6, disagree with explanation for study 7, judged to be inappropriate as subject by physician in charge |
|||
| Target sample size | 60 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kao Corporation | ||||||
| Division name | Health Care Food Research Labs | ||||||
| Zip code | 131-8501 | ||||||
| Address | 2-1-3 Bunka Sumida-ku Tokyo | ||||||
| TEL | 03-5630-7467 | ||||||
| yasunaga.kouichi@kao.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kao Corporation | ||||||
| Division name | Health Care Food Research Labs | ||||||
| Zip code | 131-8501 | ||||||
| Address | 2-1-3 Bunka Sumida-ku Tokyo | ||||||
| TEL | 03-5630-7456 | ||||||
| Homepage URL | |||||||
| yamanaka.nami2@kao.co.jp | |||||||
| Sponsor | |
| Institute | Kao Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kao Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Kao corporation IRB |
| Address | 2-1-3 Bunka, Sumida-ku, Tokyo |
| Tel | 03-5630-9220 |
| uesaka.toshio@kao.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | Unpublished due to the protocol including the intellectual property rights |
| Publication of results | Unpublished |
| Result | |||||||
| URL related to results and publications | works in progress | ||||||
| Number of participants that the trial has enrolled | 58 | ||||||
| Results | There was a significant difference in primary outcome |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | overweight |
||||||
| Participant flow | 58 participants completed and 58 subjects were incorporated into the analyses |
||||||
| Adverse events | No adverse effect related to the test diets reported |
||||||
| Outcome measures | visceral fat area |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030139 |